Skip to main content
. 2021 Jan 11;11(1):e041072. doi: 10.1136/bmjopen-2020-041072

Table 2.

Clinical characteristics based on parental history of DM

No parental history of DM (n=762) Parental history of DM (n=132) P value
Basic characteristics
 Age (years) 51.17±14.09 41.70±10.88 <0.001
 Men (%) 502 (65.9) 95 (72.0) 0.193
 BMI (kg/m2) 25.49±3.86 26.06±3.70 0.108
 WHR 0.94±0.06 0.95±0.06 0.938
 SBP (mm Hg) 135.02±18.51 133.40±17.14 0.362
 DBP (mm Hg) 83.68±12.81 85.00±12.22 0.212
 Drinking (%) 202 (26.5) 38 (28.8) 0.731
Laboratory data
 Hb (g/L) 136.71±20.02 142.73±20.02 0.003
 PLT (×109/L) 218.22±90.17 228.58±74.77 0.029
 FBG (mmol/L) 8.91±4.38 10.84±5.21 <0.001
 HbA1C (%) 10.03±2.86 10.73±2.48 0.005
 Alb (g/L) 37.08±4.95 38.12±4.44 0.057
 TC (mmol/L) 4.56±1.34 4.99±1.88 0.012
 LDL (mmol/L) 2.86±1.01 2.97±1.08 0.195
 HDL (mmol/L) 0.98±0.29 0.96±0.34 0.193
 TG (mmol/L) 2.53±3.0 3.72±4.88 0.01
 sCre (µmol/L) 69.26±39.93 63.83±24.43 0.266
 HOMA2-IR (%) 1.43±1.29 1.48±1.53 0.803
 HOMA2-B (%) 52.41±50.46 42.28±46.83 <0.001
Complications
 DKA 25 (3.3) 10 (7.6) 0.027
 HTN 305 (40.0) 47 (35.6) 0.385
Medications
 ACEI (%) 112 (14.7) 20 (15.1) 0.786
 ARB (%) 115 (15.1) 19 (14.4) 0.896
 Lipid-lowering agents (%) 479 (62.9) 85 (64.4) 0.747

HOMA2-B and HOMA2-IR were applied to estimate the function of β-cell and insulin resistance, respectively, which were calculated using fasting plasma glucose and C-peptide.

*Refers to p<0.05.

ACEI, ACE inhibitor; Alb, albumin; ARB, angiotensin receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; DKA, diabetic ketoacidosis; DM, diabetes mellitus; FBG, fasting blood glucose; Hb, haemoglobin; HbA1C, glycosylated haemoglobin; HDL, high-density lipoprotein; HOMA2-B, homoeostatic model assessment 2-B; HOMA2-IR, homoeostatic model assessment 2-insulin resistance; HTN, hypertension; LDL, low-density lipoprotein; PLT, platelet; SBP, systolic blood pressure; sCre, serum creatinine; TC, total cholesterol; TG, triglyceride; WHR, waist-to-hip ratio.